dc.date.accessioned | 2024-06-27T15:15:40Z | |
dc.date.available | 2024-06-27T15:15:40Z | |
dc.date.created | 2024-02-06T10:01:59Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Nafisi, Sara Støer, Nathalie C. Veierød, Marit B. Randel, Kristin R. Hoff, Geir Löfling, Lukas Bosetti, Cristina Botteri, Edoardo . Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway. American Journal of Gastroenterology. 2024, 1-10 | |
dc.identifier.uri | http://hdl.handle.net/10852/111312 | |
dc.description.abstract | Objectives: To examine the association between low-dose aspirin use and risk of colorectal cancer (CRC). Methods: In this nationwide cohort study, we identified individuals aged ≥50 years residing for 6 months or more in Norway in 2004-2018, and obtained data from national registers on drug prescriptions, cancer occurrence, and sociodemographic factors. Multivariable Cox regression models were used to estimate the association between low-dose aspirin use and CRC risk. Additionally, we calculated the number of CRCs potentially averted by low-dose aspirin use. Results: We included 2,186,390 individuals. During the median follow-up of 10.9 years, 579,196 (26.5%) used low-dose aspirin, and 38,577 (1.8%) were diagnosed with CRC. Current use of aspirin vs. never use was associated with lower CRC risk (hazard ratios [HR]=0.87, 95% confidence intervals [CI] 0.84-0.90). The association was more pronounced for metastatic CRC (HR=0.79; 95%CI 0.74-0.84) than regionally advanced (HR=0.89; 95%CI 0.85-0.92) and localized CRC (HR=0.93; 95%CI 0.87-1.00; Pheterogeneity=0.001). A significant trend was found between duration of current use and CRC risk: HR=0.91 (95%CI 0.86-0.95) for <3 years, HR=0.85 (0.80-0.91) for ≥3 and <5 years, and HR=0.84 (0.80-0.88) for ≥5 years of use vs. never use (Ptrend<0.001). For past use, HRs were 0.89 (95%CI 0.84-0.94) for <3 years, 0.90 (0.83-0.99) for ≥3 and <5 years, and 0.98 (0.91-1.06) for ≥5 years since last use vs. never use (Ptrend<0.001). We estimated that aspirin use averted 1073 (95%CI 818-1338) CRCs in the study period. Conclusion: In this nationwide cohort, use of low-dose aspirin was associated with a lower risk of CRC. | |
dc.description.abstract | Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway | |
dc.title.alternative | ENEngelskEnglishLow-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway | |
dc.type | Journal article | |
dc.creator.author | Nafisi, Sara | |
dc.creator.author | Støer, Nathalie C. | |
dc.creator.author | Veierød, Marit B. | |
dc.creator.author | Randel, Kristin R. | |
dc.creator.author | Hoff, Geir | |
dc.creator.author | Löfling, Lukas | |
dc.creator.author | Bosetti, Cristina | |
dc.creator.author | Botteri, Edoardo | |
cristin.unitcode | 185,53,0,0 | |
cristin.unitname | Institutt for klinisk medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2243539 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=American Journal of Gastroenterology&rft.volume=&rft.spage=1&rft.date=2024 | |
dc.identifier.jtitle | American Journal of Gastroenterology | |
dc.identifier.startpage | 1 | |
dc.identifier.endpage | 10 | |
dc.identifier.doi | https://doi.org/10.14309/ajg.0000000000002695 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0002-9270 | |
dc.type.version | PublishedVersion | |
dc.relation.project | NFR/301628 | |